These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 36726464)

  • 21. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.
    Maestri M; Santopaolo F; Pompili M; Gasbarrini A; Ponziani FR
    Front Nutr; 2023; 10():1110536. PubMed ID: 36875849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review.
    Katsagoni CN; Papachristou E; Sidossis A; Sidossis L
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32961669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
    Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    Govaere O; Petersen SK; Martinez-Lopez N; Wouters J; Van Haele M; Mancina RM; Jamialahmadi O; Bilkei-Gorzo O; Lassen PB; Darlay R; Peltier J; Palmer JM; Younes R; Tiniakos D; Aithal GP; Allison M; Vacca M; Göransson M; Berlinguer-Palmini R; Clark JE; Drinnan MJ; Yki-Järvinen H; Dufour JF; Ekstedt M; Francque S; Petta S; Bugianesi E; Schattenberg JM; Day CP; Cordell HJ; Topal B; Clément K; Romeo S; Ratziu V; Roskams T; Daly AK; Anstee QM; Trost M; Härtlova A
    J Hepatol; 2022 May; 76(5):1001-1012. PubMed ID: 34942286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatments for NAFLD: State of Art.
    Mantovani A; Dalbeni A
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD).
    Flessa CM; Kyrou I; Nasiri-Ansari N; Kaltsas G; Kassi E; Randeva HS
    J Cell Biochem; 2022 Oct; 123(10):1585-1606. PubMed ID: 35490371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
    Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
    Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
    Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
    Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
    Ratziu V; Ghabril M; Romero-Gomez M; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):28-38. PubMed ID: 30300289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immune response as a therapeutic target in non-alcoholic fatty liver disease.
    Ortiz-López N; Fuenzalida C; Dufeu MS; Pinto-León A; Escobar A; Poniachik J; Roblero JP; Valenzuela-Pérez L; Beltrán CJ
    Front Immunol; 2022; 13():954869. PubMed ID: 36300120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.